Overview

• The study published July 7 in Brain demonstrates that mouse and human induced neural stem cell grafts differentiate into mature oligodendrocytes and generate new myelin in chronic lesion sites.
• Transplanted iNSCs integrate long term in the central nervous system of progressive MS models without adverse effects, underscoring their safety.
• Functional remyelination achieved by iNSC grafts offers a potential strategy to reverse neurodegeneration rather than merely manage symptoms of progressive MS.
• Supported by the International Progressive MS Alliance, the RESTORE consortium will leverage these findings to design a groundbreaking efficacy clinical trial for neural stem cell therapy.
• RESTORE’s patient-centered framework will directly involve people with MS to ensure trial protocols align with patient needs and perspectives.